Author

Sabarinath Venniyil Radhakrishnan

Medical College of Wisconsin - Cited by 647 - cancer immunotherapy

Biography

Dr. Venniyil Radhakrishnan is graduated from the Medical College Thiruvananthapuram in 2002. He works in Salt Lake City, UT and 1 other location and specializes in Hematology, Internal Medicine, Hematology/Oncology and Medical Oncology.
Title
Cited by
Year
Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage
L Schwab, L Goroncy, S Palaniyandi, S Gautam, A Triantafyllopoulou, ...Nature medicine 20 (6), 648-654, 2014201
263
2014
Chimeric Antigen Receptor (CAR) therapy for multiple myeloma
D Atanackovic, SV Radhakrishnan, N Bhardwaj, T LuetkensBritish journal of haematology 172 (5), 685-698, 2016201
78
2016
CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
SV Radhakrishnan, T Luetkens, SD Scherer, P Davis, ER Vander Mause, ...Nature communications 11 (1), 798, 2020202
52
2020
Immunotherapies targeting CD38 in multiple myeloma
D Atanackovic, M Steinbach, SV Radhakrishnan, T LuetkensOncoimmunology 5 (11), e1217374, 2016201
39
2016
In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab
D Atanackovic, S Yousef, C Shorter, SK Tantravahi, M Steinbach, ...Leukemia (1), 317-321, 2020202
34
2020
Novel anti-myeloma immunotherapies targeting the SLAM family of receptors
SV Radhakrishnan, N Bhardwaj, T Luetkens, D AtanackovicOncoimmunology 6 (5), e1308618, 2017201
26
2017
Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation
SV Radhakrishnan, S Palaniyandi, G Mueller, S Miklos, M Hager, ...Biology of Blood and Marrow Transplantation 21 (1), 30-38, 2015201
22
2015
Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion
ML Olson, ERV Mause, SV Radhakrishnan, JD Brody, AP Rapoport, ...Leukemia 36 (7), 1943-1946, 222
20
2022
Chimeric antigen receptor (CAR) T cells specific for CD229: a potentially curative approach for multiple myeloma
SV Radhakrishnan, T Luetkens, S Yousef, N Bhardwaj, MN Steinbach, ...Blood 130, 3142, 202
17
2017
Murine cytomegalovirus immediate-early 1 gene expression correlates with increased GVHD after allogeneic hematopoietic cell transplantation in recipients reactivating from …
S Palaniyandi, SV Radhakrishnan, FJ Karlsson, KY Stokes, N Kittan, ...PLoS One 8 (4), e61841, 2013201
15
2013
Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma
M Mohan, S Nagavally, B Dhakal, SV Radhakrishnan, S Chhabra, ...Blood Advances 6 (8), 2466-2470, 2022202
13
2022
The role of surface molecule CD229 in Multiple Myeloma
M Olson, SV Radhakrishnan, T Luetkens, D AtanackovicClinical Immunology 204, 69-73, 2019201
13
2019
Oscillating expression of interleukin-16 in multiple myeloma is associated with proliferation, clonogenic growth, and PI3K/NFKB/MAPK activation
J Templin, D Atanackovic, D Hasche, SV Radhakrishnan, T LuetkensOncotarget 8 (30), 49253, 2017201
13
2017
Characterization of alginic acid extracted from Sargassum wightii and determination of its anti-viral activity of shrimp Penaeus monodon post larvae against white spot syndrome …
M Sivagnanavelmurugan, S Radhakrishnan, A Palavesam, V Arul, ...Int. J. Curr. Res. Life Sci (04), 1863-182, 2018201
7
2018
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy
S Al Hadidi, A Szabo, J Esselmann, L Hammons, M Hussain, ...Bone Marrow Transplantation 58 (4), 443-445, 2023202
7
2023
A call to arms: a critical need for interventions to limit pulmonary toxicity in the stem cell transplantation patient population
SV Radhakrishnan, GC HildebrandtCurrent hematologic malignancy reports 10, 8-17, 20120
5
2015
Elotuzumab as a novel anti-myeloma immunotherapy
SV Radhakrishnan, N Bhardwaj, M Steinbach, J Weidner, T Luetkens, ...Human Vaccines & Immunotherapeutics 13 (8), 171-177, 2017201
5
2017
The prolyl hydroxylase inhibitor dimethyl oxalyl glycine decreases early gastrointestinal GVHD in experimental allogeneic hematopoietic cell transplantation
S Palaniyandi, R Kumari, SV Radhakrishnan, E Strattan, N Hakim, ...Transplantation 104 (12), 2507, 2020202
3
2020
Current Strategies for the Immunotherapy of Multiple Myeloma.
T Luetkens, S Yousef, SV Radhakrishnan, D AtanackovicOncology (Williston Park, NY) 1 (1), 55-6, 2017201
3
2017
Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience
M Mohan, LE Rein, N Thalambedu, Y Ogunsesan, M Hussain, J Sethi, ...American journal of hematology 97 (12), E451-E45, 2022202
3
2022

Referred From: https://scholar.google.com/citations?user=3pxkGIoAAAAJ&hl=en

Cited by
Citations 647
h-index 13
i10-index 13
Recommended Journals
Open Access Journals